Rocket Pharmaceuticals Inc. announced their financial results for the second quarter of 2025, revealing a net loss of $68.9 million or $0.62 per share for the three months ending June 30, 2025. This compares to a net loss of $69.6 million or $0.74 per share for the same period in 2024. The company also reported having $271.5 million in cash, cash equivalents, and investments, which is expected to support operations until the second quarter of 2027. In response to market dynamics, Rocket Pharmaceuticals is implementing an organizational restructuring, which includes a 30% reduction in headcount and is anticipated to lower the company's 12-month cash burn by approximately 25%. Restructuring and related charges amounted to about $3.5 million in the first half of 2025. The company is shifting its strategic focus towards its AAV cardiovascular gene therapy platform. Key developments include FDA RMAT designation for RP-A601 in PKP2-ACM and the acceptance of an IND with a Fast Track designation for RP-A701 in the BAG3-DCM program. The company is pausing further investments in FA and PKD programs while exploring external strategic alternatives for them. Chris Stevens has been appointed as the new Chief Operating Officer.